← All indications
Myelodysplastic-Myeloproliferative Diseases
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.
Subtype terms (3)
More specific conditions that are subtypes of Myelodysplastic-Myeloproliferative Diseases in the MeSH hierarchy.
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
134 drugs (105 approved, 29 experimental)
- Leukemia, Myelomonocytic, Chronic
237 drugs (130 approved, 107 experimental)
- Leukemia, Myelomonocytic, Juvenile
61 drugs (45 approved, 16 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (12)
Phase 2 trials (35)
- thalidomide
- methylprednisolone
- urea
- bone autograft
- cyproheptadine
- prednisone
- etanercept
- tacrolimus
- naltrexone
- doxercalciferol
- il-3
- Filgrastim
- ganciclovir
- leukocytes
- megestrol
- allogeneic stem cells
- vitamin c
- peripheral blood lymphocytes
- stk1-ligand
- thrombopoietin
- immune globulin (human)
- sirolimus
- arsenic trioxide
- cyclosporine
- mycophenolate
- stem cells
- bexarotene
- allogeneic lymphocytes
- tocilizumab
- topotecan
- +5 more
Organizations
Organization Involved with Phase 3 Indications (22)
- Center for International Blood and Marrow Transplant Research
- Medical Research Council
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- European Working Group of MDS in Childhood
- University of Washington
- Johns Hopkins University
- Leukemia Research Foundation
- Medical College of Wisconsin
- Oregon Health and Science University
- University of Kansas
- University of Michigan
- University of Birmingham
- Mayo Clinic
- Cardiff University
- Vanderbilt University
- University of Freiburg
- European Organisation for Research and Treatment of Cancer
- State University of New York, Buffalo
- Blood and Marrow Transplant Clinical Trials Network
- HagaZiekenhuis
Organization Involved with Phase 2 Indications (39)
- ADC Therapeutics SARL
- Incyte
- Celgene
- CTI BioPharma
- Theradex
- Vion Pharmaceuticals
- National Institutes of Health (NIH)
- University of Pennsylvania
- Case Western Reserve University
- Cornell University
- Eastern Cooperative Oncology Group
- Duke University
- Temple University
- Indiana University
- Institut Paoli-Calmettes
- Northside Hospital, Inc.
- Northwestern University
- Rutgers University
- Stanford University
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Nebraska
- University of New Mexico
- University of Rochester
- University of South Florida
- Wake Forest University
- Wayne State University
- University of California, San Francisco
- University of Chicago
- University of Ulsan
- +9 more
Organization Involved with Phase 1 Indications (16)
- Pharmacyclics
- Bayer
- Bellicum Pharmaceuticals
- Constellation Pharmaceuticals
- University of Pittsburgh
- AIDS Malignancy Consortium
- Harvard University
- Ohio State University
- University of Maryland
- University of Southern California
- University of Toronto
- Yale University
- The Leukemia and Lymphoma Society
- Vasgene Therapeutics, Inc
- L K Whittier Foundation
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (4)